Email
Print
The Epinephrine Market size is estimated to reach $4.3 billion by 2027, growing at a CAGR of 8.5% during the forecast period 2022-2027. Epinephrine, also termed adrenaline, is both a hormone and a neurotransmitter. As a hormone, it is prepared and discharged by the adrenal glands, which are hat-shaped glands that perch on top of every kidney. As a central nervous system neurotransmitter, it is a chemical messenger that assists in sending nerve signals across nerve endings to another nerve cell, muscle cell or gland cell. Catecholamines (CAs) play a principal role in the management of blood pressure. Sympathetic adrenal impacts are eventually drawn out by the neurotransmitter norepinephrine and the hormone epinephrine. Epinephrine or adrenaline is usually generated by the both adrenal glands and a tiny count of neurons in the medulla oblongata. Chromaffin cells of the adrenal medulla are energized by the splanchnic nerve and secrete adrenaline (epinephrine), noradrenaline (norepinephrine), some dopamine, enkephalin and enkephalin-containing peptides and a few additional hormones into the bloodstream. A typical Epinephrine Industry Application involves the treatment of anaphylaxis which happens to cause accelerated heart rate, weak pulse and breathlessness.
The surging approval of different epinephrine products, with epinephrine
being generated by the adrenal glands
and by a tiny count of neurons in the medulla oblongata, by the U.S. Food and
Drug Administration (FDA) is set to drive the Epinephrine Market. The increasing introduction of progressive technologies and the soaring count of novel product
launches are set to propel the growth of the Epinephrine industry during the
forecast period 2022-2027. This represents the Epinephrine Industry Outlook.
Epinephrine Market Report Coverage
The “Epinephrine Market Report -
Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the
following segments in the Epinephrine
Market.
Key Takeaways
- Geographically, North America (Epinephrine Market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027, owing to the surging demand for Epinephrine in the North American region.
- Epinephrine Market growth is being driven by the rising count of cases of anaphylaxis and the launch of the generic version of epinephrine generated by adrenal glands and a tiny count of neurons in the medulla oblongata. However, the dearth of accessibility of epinephrine auto-injectors and their low-cost substitutes are some of the major factors hampering the growth of the Epinephrine Market.
- Epinephrine Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market will be provided in the Epinephrine Market report.
Epinephrine Market: Market Share (%) by Region, 2021
For More Details on This Report - Request for Sample
Epinephrine Market Segment Analysis - by Product Type
The Epinephrine Market based on
product type can be further segmented into Epinephrine Auto-Injector, Epinephrine Prefilled Syringe, Ampoules And
Vials, Combination Epinephrine Products and others. The Epinephrine Auto-Injector Segment held the largest Epinephrine Market share in 2021. Due to the rising application of Epinephrine
Auto-Injector for treatment of patients who have been concluded to be raised
hazard for anaphylaxis, including individuals with a history of anaphylactic
reactions, there is a significant growth in the market. Epinephrine injection, USP auto-injector 0.3mg and 0.15mg is an
auto-injector and a combination product including medication and device constituents.
The surging application of pocket-sized medication termed epinephrine
auto-injector to treat anaphylactic shock is further propelling the growth of
the Epinephrine Auto-Injector segment.
Furthermore, the Epinephrine Auto-Injector segment is estimated to grow
with the fastest CAGR of 9.6% during the forecast period 2022-2027 owing to the
increasing predominance of anaphylaxis which happens when the body has a hypersensitive
reaction to a substance one is allergic to, such as food, medications or insect
stings.
Epinephrine
Market Segment Analysis - by Application
The Epinephrine Market
based on the application can be further segmented into Anaphylaxis, Cardiac Arrest, Respiratory Disorders, Superficial
Bleeding and others. The Anaphylaxis Segment held the largest Epinephrine Market share in 2021. This growth is caused by the surging
application of Epinephrine for the Treatment of Anaphylaxis. Epinephrine is the
first-line treatment for anaphylaxis. Epinephrine, also called adrenaline, is a
hormone that both the adrenal glands and a tiny count of neurons in the medulla
oblongata produce in the body. The capability of Epinephrine to perform within
minutes to avert progression and reverse the symptoms of anaphylaxis is further
propelling the growth of this segment.
Furthermore, the Cardiac Arrest segment is
estimated to grow with the fastest CAGR of 9.8% during the forecast period 2022-2027, owing to the increasing
application of Epinephrine at the time of cardiopulmonary resuscitation (CPR)
to reverse cardiac arrest.
Epinephrine Market Segment Analysis - by Geography
The Epinephrine Market
based on geography can be further segmented into North America, Europe,
Asia-Pacific, South America and the Rest of the World. North America (Epinephrine
Market) held the largest Epinephrine Market share with 36% of the overall market in
2021. The growth of this region is owing to the surging count of people
with life-threatening food allergies and the increase in chronic ailments attributed
to allergies in the North American region. The existence
of strong healthcare facilities and accelerated introduction of progressive
epinephrine injections and products are further propelling the growth of the Epinephrine
industry, thereby contributing to the Epinephrine Industry Outlook, in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the surging production of generic epinephrine in the Asia-Pacific region. The greater susceptibility of people to allergy and infections and the continuous and considerable boost in the count of anaphylaxis cases are further fuelling the progress of the Epinephrine Market in the Asia-Pacific region.
Epinephrine Market Drivers:
Surging Significance of Catecholamines in Stress Response is Projected to Drive the Growth of the Epinephrine Market:
An Epinephrine range of 0.5 to 20mcg is mostly thought-out to be normal for a 24-hour period. Catecholamines are a significant portion of the stress response of the body, which can be essential in a fight-or-flight response to an anticipated threat. They are generated in the adrenal glands, the brainstem and the brain. In the brain, they behave as neurotransmitters. In the blood, they circulate and behave as hormones and are cracked down after just a few minutes. They are then discharged in the urine. Catecholamines involve neurotransmitters like dopamine, epinephrine (adrenaline) and norepinephrine (noradrenaline), which are discharged during the stress response of the body. The adrenaline rush experienced when scared is the outcome of catecholamines. The surging significance of catecholamines in stress response is therefore fuelling the growth of the Epinephrine Market during the forecast period 2022-2027.
Proliferating Applications of Epinephrine are Expected to Boost the Growth of the Epinephrine Industry:
Epinephrine, also termed adrenaline, is a hormone that both the adrenal glands and a tiny count of neurons in the medulla oblongata generate in the body. Chromaffin cells are neuroendocrine cells discovered mostly in the medulla of the adrenal glands in mammals. The chromaffin cells of the adrenal medulla give off catecholamines, adrenaline (also termed epinephrine), noradrenaline (also termed norepinephrine) and dopamine, which are synthesized from the amino acid tyrosine. The chromaffin cells discharge catecholamines: ~80% of adrenaline (epinephrine) and ~20% of noradrenaline (norepinephrine) into systemic circulation for systemic impacts on numerous organs (comparable to secretory neurons of the hypothalamus) and can also transmit paracrine signals. They are therefore termed neuroendocrine cells. Artificial epinephrine is utilized as a medicine to treat serious allergic reactions. People who experience allergies to particular foods, insect venom or other substances frequently carry an epinephrine auto-injector to self-administer the medication in emergencies. Numerous people mention this device by the brand name EpiPen. An injection of synthetic epinephrine by way of a spring-loaded syringe can serve as an emergency medical treatment for serious allergic reactions, including those that happen in response to foods, insect bites or stings, latex, medications and additional substances. Therefore, the proliferating applications of Epinephrine are driving the growth of the Epinephrine industry, further contributing to the Epinephrine Industry Outlook during the forecast period 2022-2027.
Epinephrine Market Challenge:
Challenges of Epinephrine are Hampering the Growth of the Epinephrine Market:
Epinephrine (adrenaline) belongs to a category of compounds termed catecholamines. The Pennsylvania Patient Safety Reporting System (PA-PSRS) accepted abundant reports of accidental administration of concentrated epinephrine: a high-alert medication. While it is not more susceptible to error than additional medications, epinephrine does pose a greater hazard of severe patient harm and demise when utilized in error. Based on the reports submitted to PA-PSRS and elsewhere, most of the errors including epinephrine can be traced to two issues: 1) expressing the concentration as a ratio strength instead of a metric per volume concentration and 2) disorientation between epinephrine and ephedrine. Errors with concentrated epinephrine were considerably greater than those observed with additional medicines. Investigations testing the performance of healthcare providers while dosing epinephrine find a soaring rate of errors (over 60 percent) and constant failures in administering the correct dosage. These issues are thus hampering the growth of the Epinephrine Market.
Epinephrine Industry Outlook
Novel service/product launches, partnerships, business expansions, acquisitions, collaborations and agreements are key strategies adopted by players in the Epinephrine Market. The top 10 companies in the Epinephrine Market are:
- Mylan N.V.
- Pfizer Inc.
- Teva Pharmaceuticals Industries Ltd.
- Impax Laboratories, Inc.
- Kaleo, Inc.
- Adamis Pharmaceuticals Corporation
- Bausch Health
- ALK- Abello A/S
- Sanofi S.A.
- Sandoz International GmbH
Recent Developments
- In May 2022, Pfizer planned to gain Biohaven Pharmaceuticals. Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. declared that the firms have entered into a definitive agreement under which Pfizer would gain Biohaven. Biohaven is the maker of NURTEC® ODT, an innovative dual-acting migraine therapy certified for both acute treatment and episodic avoidance of migraine in mature grown-ups. Under the terms of the agreement, Pfizer would gain all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash.
- In December 2021, Pfizer planned to acquire Arena Pharmaceuticals. Pfizer Inc. and Arena Pharmaceuticals, Inc. declared that the firms have entered into a definitive agreement under which Pfizer would gain Arena, a clinical-stage firm developing innovative potential therapies for the treatment of numerous immuno-inflammatory ailments. Under the terms of the agreement, Pfizer would gain all the outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of nearly $6.7 billion.
- In August 2021, Pfizer consented to gain Trillium Therapeutics for $2.26bn. The proposed acquisition to extend Pfizer’s pipeline comes subsequent to the firm investing $25m in Trillium last year. Pfizer has signed a definitive agreement to gain all the outstanding shares of the clinical-stage immuno-oncology firm, Trillium Therapeutics, for a proposed equity value of $2.26bn or $18.50 per share in cash. This concludes the Epinephrine Industry Outlook.
Relevant Reports:
Report Code: HCR 15591
Report Code: HCR 0590
Report Code: HCR 0222
For more Lifesciences and Healthcare Market reports, please click here